 |
|
Become an MS Research Champion How We Will Stop MS (.pdf) |
There are more potential MS therapies in development today than at any other time in history, and a variety of therapies exist, largely for those with relapsing forms of multiple sclerosis.
For some, these treatments reduce the number and severity of attacks and slow disease activity, but more must be done to stop disease progression for everyone affected by MS – including those with progressive forms.
We must find ways to stop all disease activity and prevent further progression for those who already have MS. Here’s how:
- We must better understand the role the immune system plays in the cause of MS and in ongoing disease activity
- We must pursue research leading toward clinical trials of new therapies to stop damage and progression of disability
- We must ensure that we understand health care issues and gather data to advocate for policies that enable everyone with MS to access quality care and treatment
- We must understand the mechanisms that cause tissue injury and that drive disease progression.
News Related to Stopping MS
Positive Results Announced for Aubagio in Phase III Study of People at High Risk for MS
Apr 26, 2013
Among 618 people at high risk of developing MS, significantly fewer people taking oral Aubagio® (teriflunomide, Genzyme, a Sanofi company) for two years had developed clinically definite MS than those taking placebo, Genzyme announced in a press release dated April 25, 2013.
Results Published from Phase II Trial of Daclizumab in Relapsing MS
Apr 25, 2013
Results that led to larger-scale clinical trials of daclizumab high-yield process (DAC HYP, Biogen Idec and Abbott Pharmaceuticals) have been published. The phase II SELECT trial found that this monoclonal antibody, taken by injection under the skin every four weeks, significantly reduced the average annual relapse rate and the risk of progression in a study of over 600 people with relapsing-remitting MS over a one-year trial.
Cases of PML Reported in People Taking Fumarate-based Treatments for Psoriasis - No cases reported in People with MS Taking Related Product, Tecfidera
Apr 24, 2013
The New England Journal of Medicine has published two reports from Europe of people with psoriasis who developed progressive multifocal leukoencephalopathy (PML, a viral infection of the brain that usually leads to death or severe disability) while taking fumarate-based treatments. It has not been proven that the treatment caused the infection. No such cases have been reported in people with MS taking the related product, Tecfidera™ (dimethyl fumarate, Biogen Idec), which was approved earlier this year to treat relapsing MS.
more news